Page 1778 - Hematology_ Basic Principles and Practice ( PDFDrive )

1582 Part IX Cell-Based Therapies

effector function after T cell-depleted allogeneic hematopoietic cell 30a. Gumá M, Angulo A, Vilches C, et al: Imprint of human cytomegalovirus
transplantation. Blood 113:3875–3884, 2009. infection on the NK cell receptor repertoire. Blood 104(12):3664–3671,
20. Fauriat C, Ivarsson MA, Ljunggren HG, et al: Education of human 2004.
natural killer cells by activating killer cell immunoglobulin-like receptors. 31. Foley B, Cooley S, Verneris MR, et al: Cytomegalovirus reactivation
Blood 115:1166–1174, 2010. after allogeneic transplantation promotes a lasting increase in educated
21. Foley B, Cooley S, Verneris MR, et al: NK cell education after allogeneic NKG2C+ natural killer cells with potent function. Blood 119:2665–
transplantation: dissociation between recovery of cytokine-producing 2674, 2012.
and cytotoxic functions. Blood 118:2784–2792, 2011. 32. Lopez-Verges S, Milush JM, Schwartz BS, et al: Expansion of a unique
22. Cooley S, Trachtenberg E, Bergemann TL, et al: Donors with group CD57(+)NKG2Chi natural killer cell subset during acute human
B KIR haplotypes improve relapse-free survival after unrelated hema- cytomegalovirus infection. Proc Natl Acad Sci USA 108:14725–14732,
topoietic cell transplantation for acute myelogenous leukemia. Blood 2011.
113:726–732, 2009. 33. Lee J, Zhang T, Hwang I, et al: Epigenetic Modification and
23. Cooley S, Weisdorf DJ, Guethlein LA, et al: Donor selection for Antibody-Dependent Expansion of Memory-like NK Cells in Human
natural killer cell receptor genes leads to superior survival after unrelated Cytomegalovirus-Infected Individuals. Immunity 42:431–442, 2015.
transplantation for acute myelogenous leukemia. Blood 116:2411–2419, 34. Schlums H, Cichocki F, Tesi B, et al: Cytomegalovirus infection drives
2010. adaptive epigenetic diversification of NK cells with altered signaling and
24. Cooley S, Weisdorf DJ, Guethlein LA, et al: Donor Killer Cell Ig-like effector function. Immunity 42:443–456, 2015.
Receptor B Haplotypes, Recipient HLA-C1, and HLA-C Mismatch 35. Elmaagacli AH, Steckel NK, Koldehoff M, et al: Early human
Enhance the Clinical Benefit of Unrelated Transplantation for Acute cytomegalovirus replication after transplantation is associated with a
Myelogenous Leukemia. J Immunol 192:4592–4600, 2014. decreased relapse risk: evidence for a putative virus-versus-leukemia effect
25. Venstrom JM, Pittari G, Gooley TA, et al: HLA-C-dependent preven- in acute myeloid leukemia patients. Blood 118:1402–1412, 2011.
tion of leukemia relapse by donor activating KIR2DS1. N Engl J Med 36. Green ML, Leisenring WM, Xie H, et al: CMV reactivation after
367:805–816, 2012. allogeneic HCT and relapse risk: evidence for early protection in acute
26. Impola U, Turpeinen H, Alakulppi N, et al: Donor Haplotype B of myeloid leukemia. Blood 122:1316–1324, 2013.
NK KIR Receptor Reduces the Relapse Risk in HLA-Identical Sibling 37. Romee R, Schneider SE, Leong JW, et al: Cytokine activation induces
Hematopoietic Stem Cell Transplantation of AML Patients. Front human memory-like NK cells. Blood 120:4751–4760, 2012.
Immunol 5:405, 2014. 37a. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al: Successful adoptive
27. Delgado DC, Hank JA, Kolesar J, et al: Genotypes of NK cell KIR transfer and in vivo expansion of human haploidentical NK cells in
receptors, their ligands, and Fcgamma receptors in the response of patients with cancer. Blood 105(8):3051–3057, 2005.
neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res 38. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al: Successful adoptive
70:9554–9561, 2010. transfer and in vivo expansion of human haploidentical NK cells in
28. Oevermann L, Michaelis SU, Mezger M, et al: KIR B haplotype donors patients with cancer. Blood 105:3051–3057, 2005.
confer a reduced risk of relapse after haploidentical transplantation in 39. Bachanova V, Cooley S, Defor TE, et al: Clearance of acute myeloid
children with acute lymphoblastic leukemia. Blood 124:2744–2747, leukemia by haploidentical natural killer cells is improved using IL-2
2014. diphtheria toxin fusion protein. Blood 123:3855–3863, 2014.
29. Verneris MR, Miller JS: KIR B or not to be? … that is the question for 40. Shah NN, Baird K, Delbrook CP, et al: Acute GVHD in patients receiv-
ALL. Blood 124:2623–2624, 2014. ing IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell
30. Gleason MK, Ross JA, Warlick ED, et al: CD16xCD33 bispecific killer transplantation. Blood 125:784–792, 2015.
cell engager (BiKE) activates NK cells against primary MDS and MDSC
CD33+ targets. Blood 123:3016–3026, 2014.